Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
CisThera
CisThera, a privately-held biopharmaceutical firm, focuses on creating innovative treatments for cancer and autoimmune disorders.
Sector
Subsector
Keywords
Location
Karus Therapeutics
Karus Therapeutics is developing small molecule drugs for cancer patients with limited treatment options.
Sector
Subsector
Keywords
Location
total rounds
total raised
Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company that develops and sells therapeutic products for cancer treatment.
Sector
Subsector
Keywords
Location
total rounds
total raised
FORMA Therapeutics
FORMA Therapeutics develops breakthrough oncology drugs for rare diseases and cancers.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds15
Number of Funding Rounds
Money Raised
Their latest funding was raised on 29.01.2024. Their latest round Post-IPO Equity
Co-Investors
Investors1
Number of lead investors
Number of investors
Florida Institute for the Commercialization of Florida Technology
Florida non-profit collaborates with universities to create investable companies and clean jobs.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Acquisitions1
Cimarron Medical acquired by Panbela Therapeutics
acquirer
date
type
Cimarron Medical
Cimarron Medical is a biopharmaceutical company developing treatments for pancreatic cancer.
Sector
Subsector
Location
People
Founders2
Thomas X. Neenan
Dr. Thomas X. Neenan is CEO and a founder of AbFero Pharmaceuticals. Prior to launching AbFero, Dr. Neenan was a founder and CEO of Sideris Pharmaceuticals. He also was co-founder and CSO of Panbela Therapeutics (NASDAQ: PBLA), formerly Sun BioPharma, and held executive roles at GelTex Pharmaceuticals and Genzyme. Before joining the biotech industry, Dr. Neenan led a research group focused on materials chemistry at AT&T Bell Labs. He holds a BSc (Hons) in chemistry and mathematics from University College Dublin, a PhD in materials chemistry from Penn State University, and completed his post-doctoral studies in chemistry with George H. Whitesides at Harvard University.
current job
Thomas X. Neenan
Employee Profiles10
Paul M. Herron
Chief Financial Officer & Vice President-Business Development
Clifford F. Mccurdy
Chairman & Chief Executive Officer
Thomas X. Neenan
Co-Founder, Chief Executive Officer & President
Activity
Recent News3
The graph reveals the ratio (%) of positive news articles in a chosen time range